Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NYSEAMERICAN:LCTX NASDAQ:LENZ NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$37.59+1.5%$23.39$13.36▼$38.59$1.22B1.46395,789 shs496,641 shsLCTXLineage Cell Therapeutics$1.39+2.6%$1.11$0.37▼$1.42$316.28M1.661.86 million shs1.40 million shsLENZLENZ Therapeutics$41.24+3.1%$36.06$16.53▼$42.77$1.19B0.45308,556 shs160,167 shsZYMEZymeworks$16.01+0.5%$13.97$9.03▼$17.70$1.20B1.27525,156 shs200,227 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-0.32%+16.48%+78.59%+114.48%+27.90%LCTXLineage Cell Therapeutics+0.75%+8.87%+12.50%+57.27%+48.51%LENZLENZ Therapeutics-3.19%+0.96%+5.71%+38.16%+83.03%ZYMEZymeworks+1.21%+4.87%+10.93%+30.15%+27.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$37.59+1.5%$23.39$13.36▼$38.59$1.22B1.46395,789 shs496,641 shsLCTXLineage Cell Therapeutics$1.39+2.6%$1.11$0.37▼$1.42$316.28M1.661.86 million shs1.40 million shsLENZLENZ Therapeutics$41.24+3.1%$36.06$16.53▼$42.77$1.19B0.45308,556 shs160,167 shsZYMEZymeworks$16.01+0.5%$13.97$9.03▼$17.70$1.20B1.27525,156 shs200,227 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-0.32%+16.48%+78.59%+114.48%+27.90%LCTXLineage Cell Therapeutics+0.75%+8.87%+12.50%+57.27%+48.51%LENZLENZ Therapeutics-3.19%+0.96%+5.71%+38.16%+83.03%ZYMEZymeworks+1.21%+4.87%+10.93%+30.15%+27.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.00Buy$61.5763.43% UpsideLCTXLineage Cell Therapeutics 3.00Buy$4.25204.66% UpsideLENZLENZ Therapeutics 3.00Buy$49.6022.02% UpsideZYMEZymeworks 2.90Moderate Buy$21.4333.68% UpsideCurrent Analyst Ratings BreakdownLatest LCTX, ZYME, LENZ, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025DNTHDianthus TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $65.009/12/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $44.009/9/2025DNTHDianthus TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$56.00 ➝ $63.009/9/2025DNTHDianthus TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $100.009/9/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$50.00 ➝ $67.009/8/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.008/27/2025LCTXLineage Cell TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.008/21/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $42.008/14/2025LCTXLineage Cell TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.008/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.008/5/2025LCTXLineage Cell TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$4.85M249.83N/AN/A$11.91 per share3.16LCTXLineage Cell Therapeutics$9.50M33.53N/AN/A$0.35 per share3.99LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AZYMEZymeworks$122.87M9.81N/AN/A$6.63 per share2.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$84.97M-$3.25N/AN/AN/A-2,364.56%-34.72%-32.72%11/6/2025 (Estimated)LCTXLineage Cell Therapeutics-$18.61M-$0.12N/AN/AN/A-374.84%-20.00%-12.93%11/13/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)ZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest LCTX, ZYME, LENZ, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DNTHDianthus Therapeutics-$0.86-$0.88-$0.02-$0.88$0.87 million$0.19 million8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A13.1213.12LCTXLineage Cell TherapeuticsN/A4.084.08LENZLENZ TherapeuticsN/A20.5420.54ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%LCTXLineage Cell Therapeutics62.47%LENZLENZ Therapeutics54.32%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics8.15%LCTXLineage Cell Therapeutics26.80%LENZLENZ Therapeutics6.90%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8032.19 million26.86 millionOptionableLCTXLineage Cell Therapeutics60228.36 million167.16 millionNot OptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/AZYMEZymeworks46075.17 million67.56 millionOptionableLCTX, ZYME, LENZ, and DNTH HeadlinesRecent News About These CompaniesZymeworks Inc. $ZYME Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLCSeptember 16 at 3:06 AM | marketbeat.comBrokers Set Expectations for Zymeworks FY2025 EarningsSeptember 7, 2025 | marketbeat.comEcoR1 Capital LLC Purchases 2,231,469 Shares of Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comTrexquant Investment LP Has $2.63 Million Stake in Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comBloom Burton Comments on Zymeworks FY2025 EarningsSeptember 6, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 5, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYMESeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Stake Reduced by Redmile Group LLCSeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comZymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell EngagerSeptember 2, 2025 | globenewswire.comWellington Management Group LLP Reduces Stock Holdings in Zymeworks Inc. $ZYMESeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 198,812 Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comVanguard Group Inc. Decreases Stock Position in Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Zymeworks Inc. $ZYMEAugust 31, 2025 | marketbeat.comWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCTX, ZYME, LENZ, and DNTH Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$37.58 +0.55 (+1.47%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.38 +0.04 (+2.59%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.LENZ Therapeutics NASDAQ:LENZ$41.24 +1.23 (+3.07%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Zymeworks NYSE:ZYME$16.01 +0.08 (+0.50%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
